drugset / Trial / NCT00857454
A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations
Parallel-groupOpen-labelTreatment
Summary
Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will assess the occurrence of skin safety events for a further two months of continuous use of the Testosterone MD-Lotion® (cutaneous solution) after completion of the MTE08 (NCT00702650) trial.
Timeline
- Start
- 2008-10
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Testosterone | Small molecule | 30 mg | Topical |
| Subject | Testosterone | Small molecule | 60 mg | Topical |
| Subject | Testosterone | Small molecule | 90 mg | Topical |
| Subject | Testosterone | Small molecule | 120 mg | Topical |